Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.

Schneider, Jaime L; Shaverdashvili, Khvaramze; Mino-Kenudson, Mari; Digumarthy, Subba R; Do, Andrew; Liu, Audrey; Gainor, Justin F; Lennerz, Jochen K; Burns, Timothy F; Lin, Jessica J.

Afiliação

Schneider JL; Massachusetts General Hospital Cancer Center and Department of Medicine, Boston, MA, 02114, USA.
Shaverdashvili K; Harvard Medical School, Boston, MA, 02115, USA.
Mino-Kenudson M; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, 15219, USA.
Digumarthy SR; Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15219, USA.
Do A; Massachusetts General Hospital Cancer Center and Department of Medicine, Boston, MA, 02114, USA.
Liu A; Harvard Medical School, Boston, MA, 02115, USA.
Gainor JF; Massachusetts General Hospital Cancer Center and Department of Medicine, Boston, MA, 02114, USA.
Lennerz JK; Harvard Medical School, Boston, MA, 02115, USA.
Burns TF; Massachusetts General Hospital Cancer Center and Department of Medicine, Boston, MA, 02114, USA.
Lin JJ; Harvard Medical School, Boston, MA, 02115, USA.

NPJ Precis Oncol ; 7(1): 116, 2023 Nov 03.

Article em En | MEDLINE | ID: mdl-37923925

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article